Wall Street analysts expect that Sanofi (NYSE:SNY) will report earnings per share of $0.69 for the current quarter, Zacks reports. Three analysts have provided estimates for Sanofi’s earnings. The lowest EPS estimate is $0.67 and the highest is $0.71. Sanofi posted earnings of $0.67 per share in the same quarter last year, which indicates a positive year over year growth rate of 3%. The business is expected to issue its next earnings report on Wednesday, February 14th.
According to Zacks, analysts expect that Sanofi will report full year earnings of $3.28 per share for the current year, with EPS estimates ranging from $3.18 to $3.42. For the next year, analysts forecast that the business will report earnings of $3.41 per share, with EPS estimates ranging from $3.22 to $3.66. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Sanofi.
SNY has been the topic of several recent analyst reports. Zacks Investment Research lowered Sanofi from a “hold” rating to a “strong sell” rating in a report on Friday, October 6th. BidaskClub lowered Sanofi from a “hold” rating to a “sell” rating in a report on Monday, July 24th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Sanofi in a report on Friday, September 15th. Cowen and Company reiterated a “market perform” rating and set a $52.00 target price (up from $46.00) on shares of Sanofi in a report on Tuesday, August 1st. Finally, Argus restated a “buy” rating and issued a $55.00 price target on shares of Sanofi in a report on Friday, September 1st. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company’s stock. Sanofi presently has an average rating of “Hold” and a consensus price target of $53.50.
Sanofi (NYSE:SNY) traded down $0.42 during mid-day trading on Friday, reaching $45.00. The company’s stock had a trading volume of 1,525,500 shares, compared to its average volume of 1,393,183. The company has a current ratio of 1.59, a quick ratio of 1.16 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $113,467.86, a price-to-earnings ratio of 14.20, a PEG ratio of 2.48 and a beta of 0.88. Sanofi has a 52-week low of $38.45 and a 52-week high of $50.65.
In other Sanofi news, major shareholder Sanofi purchased 105,820 shares of the stock in a transaction on Thursday, August 24th. The shares were purchased at an average price of $482.04 per share, with a total value of $51,009,472.80. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.00% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. St. James Investment Company LLC increased its position in Sanofi by 1.0% during the third quarter. St. James Investment Company LLC now owns 1,424,367 shares of the company’s stock worth $70,919,000 after buying an additional 14,494 shares during the last quarter. Eagle Asset Management Inc. grew its position in shares of Sanofi by 66.1% in the third quarter. Eagle Asset Management Inc. now owns 10,807 shares of the company’s stock valued at $537,000 after purchasing an additional 4,302 shares during the last quarter. TD Asset Management Inc. grew its position in shares of Sanofi by 9.4% in the third quarter. TD Asset Management Inc. now owns 155,886 shares of the company’s stock valued at $7,762,000 after purchasing an additional 13,343 shares during the last quarter. Morningstar Investment Services LLC grew its position in shares of Sanofi by 7.7% in the third quarter. Morningstar Investment Services LLC now owns 733,038 shares of the company’s stock valued at $36,498,000 after purchasing an additional 52,709 shares during the last quarter. Finally, Assetmark Inc. grew its position in shares of Sanofi by 34.4% in the third quarter. Assetmark Inc. now owns 158,305 shares of the company’s stock valued at $7,882,000 after purchasing an additional 40,484 shares during the last quarter. 9.36% of the stock is currently owned by hedge funds and other institutional investors.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.